Aethlon Medical starts collaborative biomarker plan to review neurodegenerative disease Aethlon Medical, Inc. announced today that it has initiated a collaborative biomarker discovery program with the Center for the analysis of Traumatic Encephalopathy at Boston University College of Medicine and the Sports activities Legacy Institute http://www.sildenafill.org/sleep-deprivation.html . In the collaboration, Aethlon will analyze mind tissue of professional sports athletes who suffered from Chronic Traumatic Encephalopathy during their loss of life and from people without any proof brain disease. CTE is a progressive neurodegenerative disease caused by human brain trauma but with unclear genetic and environmental risk factors.
Juergen Engel, Ph. D., President and CEO of Aeterna Zentaris stated, We are very happy with AEZS-108 gaining orphan medicinal product designation for ovarian cancers from European authorities, after having been granted orphan-drug designation by the FDA especially. This means that with both these orphan designations, AEZS-108 would be given extra market exclusivity security in Europe and also in the United States for the treatment of ovarian cancer. We have now look forward to reporting the final outcomes from our ongoing European Phase 2 research in ovarian and endometrial cancer tumor, later this year.